N-acetyl-L-cysteine depresses cardiac performance in patients with septic shock

Critical Care Medicine

Volumn 24, Issue 8, 1996, Pages 1302-1310

  Peake, Sandra L ^a   Moran, John L ^a   Leppard, Phillip I ^b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

adjunctive therapy; antioxidants; cardiac performance; critical illness; hemodynamics; left ventricular stroke work; N acetyl L cysteine; organ failure; septic shock

Indexed keywords

ACETYLCYSTEINE;

ADULT; AGED; ARTERIAL GAS; ARTERIAL OXYGEN TENSION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE WORK; HEART STROKE VOLUME; HEMODYNAMICS; HUMAN; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; OXYGEN TRANSPORT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK;

EID: 0029807263     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199608000-00006     Document Type: Article

References (43)

1. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al: Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991; 324: 429-436
2. Warren HS, Danner RL, Munford RS: Anti-endotoxin monoclonal antibodies. N Engl J Med 1992; 326:1153-1157
3. Fisher CJ Jr, Dhainaut J-F, Opal SM, et al: Recombinant interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial. JAMA 1994; 271:1836-1843
4. Flanagan RJ, Meredith TJ: Use of N-acetyl cysteine in clinical toxicology. Am J Med 1991; 91(Suppl 3C):131S-139S
5. Torresi J, Horowitz JD, Dusting GJ: Prevention and reversal of tolerance to nitroglycerin with N-acetylcysteine. J Cardiovasc Pharmacol 1985; 7:777-783
6. Ferrari R, Ceconi C, Curello S, et al: Oxygen free radicals and myocardial damage: Protective role of thiol-containing agents. Am J Med 1991; 91(Suppl 3C):95S-105S
7. Peristeris P, Clark BD, Gatti S, et al: N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production. Cell Immunol 1992; 140: 390-399
8. Stamler J, Mendelsohn ME, Amarante P, et al: N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res 1989; 65:789-795
9. Jensen T, Kharazmi A, Schiotz PO, et al: Effect of oral N-acetylcysteine administration on human blood neutrophil and monocyte function. APMIS 1988; 96:62-67
10. Bernard GR, Lucht WD, Niedermeyer ME, et al: Effect of N-acetyl cysteine on the pulmonary response to endotoxin in the awake sheep and upon in vitro granulocyte function. J Clin Invest 1984; 73:1772-1784
11. Keays R, Harrison PM, Wendon JA, et al: Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: A prospective trial. BMJ 1991; 30:1026-1029
12. Bone RC: Sepsis, the sepsis syndrome, multi-organ failure: A plea for comparable definitions. Ann Intern Med 1991; 114:332
13. Prescott LF, Donovan JW, Jarvie DR, et al: The disposition and kinetics of intravenous N-acetylcysteine with paracetamol overdosage. Eur J Clin Pharmacol 1989; 37:501-506
14. Bernard GR: N-acetylcysteine in experimental and clinical acute lung injury. Am J Med 1991; 91(Suppl 3C): 54S-59S
15. Pocock SJ: Clinical trials: A Practical Approach. Chichester, UK, John Wiley & Sons, 1983, pp 67-89
16. Abraham E, Bland RD, Coba JC, et al: Sequential cardiorespiratory patterns associated with outcome in septic shock. Chest 1984; 85:75-80
17. Moran JL, O'Fathartaigh MS, Peisach AR, et al: Epinephrine as an inotropic agent in septic shock: A dose profile analysis. Crit Care Med 1993; 21:70-77
18. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
19. Ramsay MA, Savage TM, Simpson BR, et al: Controlled sedation with alphaxalone/alphadolone. BMJ 1974; 2: 656-659
20. Gray R, Shah P, Singh B, et al: Low cardiac output states after open heart surgery. Chest 1981; 80:16-22
21. Sato Y, Matsuzawa H, Eguchi S: Comparative study of effects of adrenaline, dobutamine and dopamine on systemic haemodynamics and renal blood flow in patients following open heart surgery. Jpn Circ J 1982; 46:1059-1072
22. Knaus WA, Draper EA, Wagner DP, et al: Prognosis in acute organ-system failure. Ann Surg 1985; 202:685-693
23. Rockett KA, Awburn MA, Aggarwal BB, et al: In vivo induction of nitrite and nitrate by tumor necrosis factor, lymphotoxin, and interleukin-1: Possible roles in malaria. Infect Immun 1992; 60:3725-3730
24. Peake SL, Moran JL, Smith D: Plasma nitrite and nitrate levels in septic shock. Anaesth Intensive Care 1994; 22:226-227
25. Hayes MA, Timmins AC, Yau EH, et al: Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330:1717-1722
26. Suter PM, Domenighetti G, Schaller MD, et al: N-acetylcysteine enhances recovery from acute lung injury in man. Chest 1994; 105:190-194
27. Markert M, Schaller MD, Laurent TH, et al: Oxidant-antioxidant balance in granulocytes during adult respiratory distress syndrome: Effect of N-acetylcysteine. Abstr. Am Rev Respir Dis 1992; 145:A570
28. Jepsen S, Herlevsen P, Knudsen P, et al: Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: A prospective, randomized, placebo-controlled study. Crit Care Med 1992; 20:918-923
29. Zhang H, Spapen H, Nguyen DN, et al: Protective effects of N-acetyl-L-cysteine in endotoxemia. Am J Physiol 1994; 266:H1746-1754
30. DePablo R, Lorente JA, Landín L, et al: Hemodynamic effects of N-acetylcysteine in patients with sepsis. Abstr. Medicina Intensiva 1993; 17(Suppl 1):S168
31. Harrison PM, Wenden JA, Gimson A, et al: Improvement by N-acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 1991; 324:1852-1857
32. Spies CD, Reinhart K, Witt I, et al: Influence of N-acetylcysteine on direct indicators of tissue oxygenation in septic shock patients: Results from a prospective, randomized, double-blind study. Crit Care Med 1994; 22:1738-1746
33. Ellrodt AG, Riedinger MS, Kimchi A, et al: Left ventricular performance in septic shock: Reversible segmental and global abnormalities. Am Heart J 1985; 110:402-409
34. Schreuder WO, Schneider AJ, Groenveld AJ, et al: Effect of dopamine vs norepinephrine on hemodynamics in septic shock. Emphasis on right ventricular performance. Chest 1989; 85: 1282-1288
35. Ognibene FP, Parker MM, Natanson C, et al: Depressed left ventricular performance; response to volume infusion in patients with sepsis and septic shock. Chest 1988; 93:903-910
36. Snell RJ, Parrillo JE: Cardiovascular dysfunction in septic shock. Chest 1991; 99:1000-1009
37. Gutierrez G, Bismar H, Dantzker D, et al: Comparison of gastric intramucosal pH with measurements of oxygen transport and consumption in critically ill patients. Crit Care Med 1992; 20: 451-457
38. Brady AJB, Poole-Wilson SE, Harding SE, et al: Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol 1992; 263:H1963-H1966
39. Finkel MN, Oddis CV, Jacob TD, et al: Negative inotropic effect of cytokines on the heart mediated by nitric oxide. Science 1992; 257:387-389
40. Harman LS, Mottley C, Mason RP: Free radical metabolites of L-cysteine oxidation. J Biol Chem 1984; 259:5606-5611
41. Ruffman R, Wendel A: GSH rescue by N-acetylcysteine. Klin Wochenschr 1991; 69:857-862
42. Jardin F, Valtier B, Beauchet A, et al: Invasive monitoring combined with two-dimensional echocardiographic study in septic shock. Intensive Care Med 1994; 20:550-554
43. Sunman W, Hughes AD, Sever PS: Anaphylactoid response to intravenous acetylcysteine. Lancet 1992; 339:1231-1232